A large-scale clinical study from The National Cancer Institute (NCI) demonstrated that x-ray CT screening sharply reduced lung cancer deaths by detecting cancers at relatively early stages. Patients screened with x-ray CT were 20% less likely to die from lung cancer. Annual screening by x-ray CT detects lung cancers in their earliest stage, when survival is most promising. However, the study also showed that low-dose CT scans tend to have a high false positive rate.
A major milestone for lung cancer, the Centers for Medicare and Medicaid approved reimbursing low-dose CT scans in a high-risk group of patients (ages 55-77 who have smoked one pack of cigarettes a day for 30 years) in February 2015.
LuCED does not use radiation. Rather, it uses a sputum sample that can be collected through spontaneous coughs over a three-day period using a take-home test kit. LuCED kits are shipped to the VisionGate Biosignatures Laboratory (VBL) and then samples are processed on our proprietary Cell-CT technology, a component of LuCED. The first automated 3D cell imaging platform, this revolutionary technology computes sub-micron resolution biosignatures from intact cells. Cell classifiers then automatically identify abnormal cells in sputum. Please view the Cost-Effectiveness study conducted by the University of Arizona.
VisionGate currently has collaborations or pending IRBs with:
|NYU Langone Cancer Center||Kaiser Permanente|
|Fred Hutchinson Cancer Research Center||Swedish Cancer Institute|
|Memorial Sloan Kettering||Toronto General Hospital|
|Cancer Treatment Centers of America||Dignity Health|
|Oregon Health & Science University||University of Navarra (Spain)|
|Aristotle University (Greece)|
To discuss opportunities, please contact VisionGate at 602.354.8862 or send an email to firstname.lastname@example.org.